MYGN 241220 14.00P (MYGN241220P14000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MYGN241220P14000

Watchlist

0.40
0.000.00%

15min DelayTrading Dec 9 12:35 ET

0.00High0.00Low

Intraday

5D
Daily

News

BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13
Moomoo NewsDec 13 08:33 ET · Ratings
Top Premarket Decliners
MT NewswiresDec 12 07:51 ET
Express News | Myriad Genetics Inc : Jefferies Cuts Target Price to $13 From $15
ReutersDec 12 01:47 ET
Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025
BenzingaDec 11 02:35 ET
Myriad Genetics Talks With UnitedHealthcare on Insurance Exclusion Might Extend Into 2025
WSJDec 10 19:01 ET
Myriad Genetics: During 3Q Earnings Call Provided Estimate of 2024 Fincl Impact of UNH's Updated Medical Policy, Myriad Reaffirms Estimate >MYGN
Dow JonesDec 10 18:37 ET

Comments

905745367

Dec 6 09:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 20 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics